Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Lennox JL"'
Autor:
Lucas, GM, Ross, MJ, Stock, PG, Shlipak, MG, Wyatt, CM, Gupta, SK, Atta, MG, Wools-Kaloustian, KK, Pham, PA, Bruggeman, LA, Lennox, JL, Ray, PE, Kalayjian, RC
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 59, iss 9
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherenc
Autor:
Ofotokun, I, Na, LH, Landovitz, RJ, Ribaudo, HJ, McComsey, GA, Godfrey, C, Aweeka, F, Cohn, SE, Sagar, M, Kuritzkes, DR, Brown, TT, Patterson, KB, Para, MF, Leavitt, RY, Villasis-Keever, A, Baugh, BP, Lennox, JL, Currier, JS, A525, ACTGA
Publikováno v:
Ofotokun, I; Na, LH; Landovitz, RJ; Ribaudo, HJ; McComsey, GA; Godfrey, C; et al.(2015). Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. CLINICAL INFECTIOUS DISEASES, 60(12), 1842-1851. doi: 10.1093/cid/civ193. UCLA: Retrieved from: http://www.escholarship.org/uc/item/99f752jd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::ca9f6cd4ea9b0e6b3ddd06cb3cc4970a
http://www.escholarship.org/uc/item/99f752jd
http://www.escholarship.org/uc/item/99f752jd
Publikováno v:
Lennox, JL; Landovitz, RJ; Ribaudo, HJ; Ofotokun, I; Na, LH; & Godfrey, C. (2014). Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. A randomized, controlled equivalence trial (vol 161, pg 461, 2014). ANNALS OF INTERNAL MEDICINE, 161(9), 680-680. doi: 10.7326/L14-5021-7. UCLA: Retrieved from: http://www.escholarship.org/uc/item/5dw3k6md
ANNALS OF INTERNAL MEDICINE, vol 161, iss 9
ANNALS OF INTERNAL MEDICINE, vol 161, iss 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0bd83b0324f5dd8dc3a35d5510f7834b
http://www.escholarship.org/uc/item/5dw3k6md
http://www.escholarship.org/uc/item/5dw3k6md
Publikováno v:
Annals of Internal Medicine, vol 161, iss 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::7497da494b0fd211de45836bf8010924
https://escholarship.org/uc/item/5dw3k6md
https://escholarship.org/uc/item/5dw3k6md
Publikováno v:
Lennox, JL; Landovitz, RJ; Ribaudo, HJ; Ofotokun, I; Na, LH; & Godfrey, C. (2014). Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (vol 161, pg 461, 2014). ANNALS OF INTERNAL MEDICINE, 161(7). UCLA: Retrieved from: http://www.escholarship.org/uc/item/29s15041
ANNALS OF INTERNAL MEDICINE, vol 161, iss 7
ANNALS OF INTERNAL MEDICINE, vol 161, iss 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::118da61bc533ad201313753c447d6f4d
http://www.escholarship.org/uc/item/29s15041
http://www.escholarship.org/uc/item/29s15041
Autor:
Lennox, JL, Landovitz, RJ, Ribaudo, HJ, Ofotokun, I, Na, LH, Godfrey, C, Kuritzkes, DR, Sagar, M, Brown, TT, Cohn, SE, McComsey, GA, Aweeka, F, Fichtenbaum, CJ, Presti, RM, Koletar, SL, Haas, DW, Patterson, KB, Benson, CA, Baugh, BP, Leavitt, RY, Rooney, JF, Seekins, D, Currier, JS, ACTG A5257 Team
Publikováno v:
Annals of internal medicine, vol 161, iss 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bcffb6f92b99d5dafab8835ce14a7997
https://escholarship.org/uc/item/2mn328qr
https://escholarship.org/uc/item/2mn328qr
Autor:
Eron, Jj, Cooper, Da, Steigbigel, Rt, Clotet, B, Gatell, Jm, Kumar, Pn, Rockstroh, Jk, Schechter, M, Markowitz, M, Yeni, P, Loutfy, Mr, Lazzarin, A, Lennox, Jl, Strohmaier, Km, Wan, H, Barnard, Rj, Nguyen, By, Teppler, H, Vullo, Vincenzo, BENCHMRK Study Teams
Publikováno v:
Eron, J J, Cooper, D A, Steigbigel, R T, Clotet, B, Gatell, J M, Kumar, P N, Rockstroh, J K, Schechter, M, Markowitz, M, Yeni, P, Loutfy, M R, Lazzarin, A, Lennox, J L, Strohmaier, K M, Wan, H, Barnard, R J, Nguyen, B-Y T, Teppler, H, BENCHMRK Study Teams & Pedersen, C 2013, ' Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies : final results of two randomised, placebo-controlled trials ', The Lancet Infectious Diseases (Portuguese Edition), vol. 13, no. 7, pp. 587-596 . https://doi.org/10.1016/S1473-3099(13)70093-8
Summary Background Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase strand-transfer inhibitor. We report final results of BENCHMRK-1 and BENCHMRK-2 combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa16c338a311ef6d539b5828cebeecb
https://portal.findresearcher.sdu.dk/da/publications/d6e3c5ce-57f2-4108-93c2-3f8bb5182ca3
https://portal.findresearcher.sdu.dk/da/publications/d6e3c5ce-57f2-4108-93c2-3f8bb5182ca3
Autor:
Steigbigel, Rt, Cooper, Da, Teppler, H, Eron, Jj, Gatell, Jm, Kumar, Pn, Rockstroh, Jk, Schechter, M, Katlama, C, Markowitz, M, Yeni, P, Loutfy, Mr, Lazzarin, A, Vullo, Vincenzo, Lennox, Jl, Clotet, B, Zhao, J, Wan, H, Rhodes, Rr, Strohmaier, Km, Barnard, Rj, Isaacs, Rd, Nguyen, By, BENCHMRK STUDY TEAMSA
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0568c65650e9d90f5d69e7bb1f8c7724
http://hdl.handle.net/11573/85920
http://hdl.handle.net/11573/85920
Autor:
Steigbigel, Rt, Cooper, Da, Kumar, Pn, Eron, Je, Schechter, M, Markowitz, M, Loutfy, Vullo, Vincenzo, Lennox, Jl, Gatell, Jm, Rockstroh, Jk, Katlama, C, Yeni, P, Lazzarin, A, Clotet, B, Zhao, J, Chen, J, Ryan, Dm, Rhodes, Rr, Killar, Ja, Gilde, Lr, Strohmaier, Km, Meibohm, Ar, Miller, Md, Hazuda, Dj, Nessly, Ml, Dinubile, Mj, Isaacs, Rd, Nguyen, By, Teppler, H, BENCHMRK STUDY TEAMS
Background: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. Methods: We conducted two identical trials in different geographic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce129d1ea451fff329dd3bee80d5d2a
http://hdl.handle.net/11573/85776
http://hdl.handle.net/11573/85776
Autor:
Cooper, Da, Steigbigel, Rt, Gatell, Jm, Rockstroh, Jk, Katlama, C, Yeni, P, Lazzarin, A, Clotet, B, Kumar, Pn, Eron, Je, Schechter, M, Markowitz, M, Loutfy, Mr, Lennox, Jl, Zhao, J, Chen, J, Ryan, Dm, Rhodes, Rr, Killar, Ja, Gilde, Lr, Strohmaier, Vullo, Vincenzo, Meibohm, Ar, Miller, Md, Hazuda, Dj, Nessly, Ml, Dinubile, Mj, Isaacs, Rd, Teppler, H, Nguyen, By, BENCHMRK STUDY TEAMS
Background: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfd904b9414218980a2d17b85e46901
http://hdl.handle.net/11573/85775
http://hdl.handle.net/11573/85775